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Highlights 
 
 Frontotemporal dementia is the second most common form of young 
onset dementia. 
 There is much clinical, pathological and genetic heterogeneity within FTD. 
 Mouse models focusing predominantly on recapitulating neuropathological 
and molecular changes of disease have been developed, with most transgenic 
lines expressing a single specific protein or genetic mutation.  
 Together with the species-typical presentation of functional deficits, this 
makes generalized conclusions drawn from these models that are directly 
translatable to humans difficult. 
 Understanding the phenotypical presentations in mice and how they may 
relate to clinical symptomology in humans is essential for advancing 
translation in FTD. 
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Abstract 
Frontotemporal dementia (FTD) is the second most common cause of young onset dementia. 
It is increasingly recognized that there is a clinical continuum between FTD and amyotrophic 
lateral sclerosis (ALS). At a clinical, pathological and genetic level there is much 
heterogeneity in FTD, meaning that our understanding of this condition, pathophysiology and 
development of treatments has been limited. A number of mouse models focusing 
predominantly on recapitulating neuropathological and molecular changes of disease have 
been developed, with most transgenic lines expressing a single specific protein or genetic 
mutation. Together with the species-typical presentation of functional deficits, this makes the 
direct translation of results from these models to humans difficult. However, understanding 
the phenotypical presentations in mice and how they relate to clinical symptomology in 
humans is essential for advancing translation. Here we review current mouse models in FTD 
and compare their phenotype to the clinical presentation in patients. 
 
Introduction 
The term frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders 
characterized by atrophy of the frontal and anterior temporal lobes of the brain. Prevalence 
studies suggest that FTD is the second most common cause of young onset dementia 
(Ratnavalli et al., 2002; Rosso et al., 2003). Two main clinical syndromes of FTD exist, based 
on the predominant clinical features at presentation: behavioural variant FTD (bvFTD), where 
there is deterioration in social function and personality; and primary progressive aphasia 
(PPA), with an insidious decline in language skills. PPA is further subdivided based on the 
nature of language breakdown into semantic variant primary progressive aphasia (sv-PPA), 
and non-fluent or agrammatic aphasia (progressive non-fluent aphasia: PNFA) (Gorno-
Tempini et al., 2011; Hodges and Patterson, 2007). FTD overlaps with ALS at a clinical, 
genetic and pathological level (Mitsuyama and Inoue, 2009), a position confirmed with the 
discovery of the C9ORF72 repeat expansion in FTD, FTD-ALS and ALS cases (Hodges, 
2012).   
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Each of the FTD syndromes presents with distinct clinical symptoms, neuroimaging, and 
pathological profiles (Table 1). Considerable overlap and heterogeneity exist within and 
between the syndromes, with limited correlations between clinical phenotype, underlying 
pathology and genotype. Given this complexity, the development of animal models of FTD 
has proven difficult. Currently available mouse models focus on the genetic causes and 
pathological changes and these only imperfectly correlate with clinical phenotypes. Here, we 
review current transgenic mouse models and compare their phenotypes to clinical features 
and functional deficits in FTD, which may guide the development of disease-modifying 
therapies. 
 
Pathology of FTD 
Both sporadic and autosomal dominant FTD are associated with a range of underlying 
pathologies, classified according to the protein predominantly accumulating in patients‟ 
brains. These proteins include the microtubule-associated protein tau, with different tau 
isoforms being affected in FTD subtypes such as 4-repeat tau (progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD) or globular glial tauopathy (GGT) that is 
characterized neuropathologically by widespread globular oligodendroglial and astrocytic tau 
inclusions (Ahmed et al., 2013), 3-repeat tau (Pick‟s disease), and mixed 3- and 4-repeat tau 
forms;TAR-DNA binding protein (TDP)-43 (type A to D; for details see (Mackenzie et al., 
2011)); and fused in sarcoma (FUS). In bvFTD, any of these pathological variants can be 
found, with tau or TDP-43 positive cases found at similar frequencies (Josephs et al., 2011; 
Seelaar et al., 2011). In sv-PPA the predominant pathology is TDP type C (Josephs et al., 
2011; Rohrer et al., 2010). The pathology of the other language variants is more variable and 
includes tauopathies, and TDP-43 proteinopathies. The co-occurrence of FTD and ALS is 
strongly suggestive of an underlying TDP-43 pathology (typically type B) (Seelaar et al., 
2011). Recent research has suggested that FTD and ALS may potentially result from a 
contiguous (almost „prion-like‟) spread (Braak et al., 2013; Ludolph and Brettschneider, 
2015; Tan et al., 2015). This occurs in a recognised centrifugal pattern with 4 stages of spread 
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in ALS beginning in the motor neocortex, progressing to the spinal cord and brainstem, with 
involvement of fronto-parietal regions and finally the temporal lobes (Brettschneider et al., 
2013). Such a pattern of spread may explain the development of cognitive symptoms in ALS 
and the spectrum of ALS and FTD. In behavioural variant FTD (bvFTD) pathological spread 
has been suggested to develop with a fronto-occipital gradient involving initially the frontal 
regions, and then pre-motor, primary motor, parietal and occipital cortex (Brettschneider et 
al., 2014). 
 
Genetic causes of FTD 
About 25-33% of FTD patients have a family history with an autosomal dominant pattern of 
inheritance (Rohrer et al., 2009; Rohrer and Warren, 2011; Rohrer et al., 2015a; Rohrer et al., 
2015b), most commonly associated with bvFTD (Seelaar et al., 2008). The three most 
common genes involved in FTD are C9ORF72, microtubule-associated protein tau (MAPT) 
and progranulin (GRN). Mutations in other, much less frequent, gene loci include VCP, 
CHMP2B, FUS, TARBP, DCTN1 and SQSTM1. The frequency of each mutation varies 
according to the geographical location. In a USA-based cohort (DeJesus-Hernandez et al., 
2011) C9ORF72 was the most common mutation, whereas in a Dutch cohort (Simon-Sanchez 
et al., 2012) MAPT mutations were more common, and in a UK-based cohort C9ORF72 
expansions and MAPT mutations occurred with equal frequency (Mahoney et al., 2012). 
Clinical phenotypes vary across the different genetic syndromes, but certain phenotypes are 
more commonly associated with specific mutations. For GRN mutations, the most common 
phenotypes are bvFTD, followed by PNFA and corticobasal syndrome (Chen-Plotkin et al., 
2011; Yu et al., 2010). MAPT mutations are also most frequently associated with bvFTD, but 
language presentations including semantic impairment have also been described (Seelaar et 
al., 2008). For both MAPT and GRN mutations, patients can present with parkinsonian motor 
symptoms (Rohrer and Warren, 2011). Therefore, extrapolating from the clinical presentation 
to the underlying pathology or genetic abnormality remains inaccurate. 
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Rationale to model FTD in mice 
Given the heterogeneity of FTD, a wide range of transgenic mouse models have been 
designed, predominantly aiming at recapitulating neuropathological and molecular changes of 
disease. Mice, as the most commonly used model organism, have a neuronal network similar 
to humans and allow for molecular and functional studies at the gene and protein level 
(Roberson, 2012). As model systems, however, most transgenic lines focus on a specific 
protein or genetic mutation. Together with the species-typical presentation of functional 
deficits, this limits the extent to which we can generalize from findings from these models to 
humans. Therefore, understanding the phenotypical presentations in mice and how they relate 
to clinical symptomology and functional deficits in humans is essential for advancing 
translation.  
Importantly, mouse models of FTD offer the potential to help understand the pathological 
mechanisms that underlie the clinical features of the disease in vivo. A major advantage of 
these models is that they allow for the monitoring of early pathological changes, which is 
difficult to achieve in humans with the current diagnostic standards. A plethora of in vivo and 
ex vivo techniques enable studying pathological changes in mouse models up to the molecular 
level. Animal models also offer the potential to establish proof-of-principle evidence for 
targeting specific pathomechanisms, for example by using genetic tools such as knockout 
mice, or to trial treatments and examine their effects on underlying pathological processes at 
different (early) disease stages. For example in Alzheimer‟s disease, a number of treatments 
have shown promise at the mouse model level, yet extrapolating these findings to humans has 
been troublesome. 
In FTD, which predominantly involves emotional behavioral and language changes – 
cognitive domains that might lack clear equivalents in other species – finding animal models 
that reflect these changes and functional deficits has proven difficult. On the other hand, 
recently pervasive changes in physiology and metabolism in FTD have been suggested, which 
may be easier and more valid to study in mouse models, including their impact on 
behavioural and cognitive changes (Ahmed et al., 2016c; Fletcher et al., 2015). Although this 
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review focuses on mouse models of FTD and their potential contribution to understanding 
disease, other species – both of lower (e.g. C. elegans or Drosophila) or higher order (e.g. 
primates) – are likely to contribute within their own realms. Accordingly, no single species 
will likely be sufficient to capture the marked heterogeneity of FTD presentations and 
combinations across mice, and other species may be required. 
 
A new approach: examining clinical features/functional impairment in FTD and 
transgenic mouse models 
Transgenic mouse models, alone or in combination, have been key to understanding 
fundamental molecular pathomechanisms in FTD and other neurodegenerative conditions 
(Boxer et al., 2013; Roberson, 2012) [For a list and description of currently available mouse 
models see http://www.alzforum.org/research-models/search]. There is little doubt that this 
will continue to be the case and that these models will provide in-depth understanding of 
underlying pathomechanisms. However, given the complexity of FTD genetics and pathology 
and the heterogeneous phenotypes across mouse models in terms of pathology and functional 
impairments, it is important to assess existing and novel transgenic mouse models by taking 
the clinical symptoms and functional deficits of human FTD into account. This may establish 
confidence in mouse model-based therapeutic developments. A holistic approach where 
multiple models are examined based on functional impairments in relation to clinical 
presentations and functional deficits in humans may facilitate conclusions that will aid 
understanding of brain networks involved. This will in turn aid earlier diagnoses and targeting 
of treatments. Therefore, we review FTD mouse models in the context of the functional 
impairments seen in human FTD including behavioral, socioemotional, memory, language, 
eating and metabolism, and motor. Figure 1 shows the specific phenotypes reported in a 
selection of current transgenic mouse models of FTD, and proposed future directions. 
 
Behavioural changes in FTD 
Behavioral changes in humans 
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Assessment of behavioral changes represents a cornerstone of the investigation of bvFTD, 
forming the basis of the current diagnostic criteria (Rascovsky et al., 2011). Patients with 
bvFTD typically present with changes in behavior ranging from apathy, reduced motivation, 
inertia, and a lack of interest in previous hobbies(Piguet et al., 2011), to disinhibition with 
impulsive and often socially inappropriate actions, such as overspending, gambling, or 
sexually inappropriate remarks (Rascovsky et al., 2011). Mental rigidity and stereotypical 
behavior are also widely reported by caregivers, leading to alterations in food preferences and 
eating behavior (see below). Interestingly, recent studies have elucidated commonalities in 
the neural substrates of behavioral changes in FTD. For example, both disinhibited 
(Hornberger et al., 2011) and apathetic (Go et al., 2012) behaviors relate to atrophy in the 
orbitofrontal cortex, one of the core sites of early pathology (Seeley, 2008).  
 
Behavioral changes in mouse models 
Concerted efforts have been directed at modeling behavioral changes and socioemotional 
dysfunction in transgenic mouse models of FTD (Roberson, 2012). Behavioural changes 
including disinhibition and apathy have been reported in mutant tau transgenic mouse lines. 
These specific behavioral changes display in mice as hyperactivity assessed in the open field 
arena (with increased locomotor activity and altered exploration patterns of the novel 
environment), or reduced anxiety in the elevated plus maze, light/dark chamber, and cued 
fear-conditioning paradigms (Cook et al., 2014; Pennanen et al., 2006; Przybyla et al., 2016; 
Van der Jeugd et al., 2016). The contribution of fear-associated memory deficits, however, 
remains unclear. These types of behavioral alterations in tau transgenic mice are thought to 
result mainly from pathology in the amygdala, although detailed investigations of the 
orbitofrontal cortex integrity are lacking, despite the use of pan-neuronal promoters that drive 
expression throughout the forebrain. This may be partly due to studies focusing in their 
behavioral analysis on well-defined anatomical structures, such as the hippocampus and 
amygdala (Pennanen et al., 2004). Interestingly, young tau transgenic mice display impaired 
nest-building behavior, suggesting apathy (another common symptom observed in FTD 
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patients) (Warmus et al., 2014), or decreased attention. Recently a forebrain-specific 
(CaMKIIα promoter), human mutated Tau (hTauP301L+R406W) knock-in mouse was 
generated which showed heightened anxiety and depressive/ apathetic behavior (Koss et al., 
2016). Similar to tau transgenic mice, GRN knockout mice display impaired fear conditioning 
(Filiano et al., 2013) and remain immobile for longer periods in the forced swim test (Yin et 
al., 2010), which may relate to a depressive-like state. This suggests a complex alteration to 
emotional behavior in GRN knockout lines. A recent adeno-associated virus (AAV)-based 
model expressing human C9ORF72 poly-GC-repeats similarly presented with hyperactivity 
and anxiety-like exploration in the open field arena (Chew et al., 2015). While two transgenic 
mouse lines expressing bacterial artificial chromosomes (BACs) containing the full human 
C9ORF72 gene and ~500 or ~1,000 poly-GC repeats resulted in disease-like 
neuropathological changes (RNA foci and RAN dipeptides) without behavioral deficits or 
neurodegeneration (O'Rourke et al., 2015; Peters et al., 2015), a recent C9ORF72 BAC mouse 
line with ~500 poly-GC repeats presented with both neuropathological changes, paralysis, 
reduced survival, and also anxiety (Liu et al., 2016). The introduction of these C9ORF72 
BAC models will provide the basis for function in-depth studies of associated 
pathomechanisms in vivo. 
 
In a number of mouse models, anxiety paradigms are used, such as the elevated plus maze or 
open field arena. However, locational memory dysfunction may significantly contribute to the 
displayed behavior, which needs to be taken into consideration when interpreting this data 
(Dvorkin et al., 2008). Reduced levels of anxiety in mice could be interpreted as excessive 
risk-taking behavior and/or disinhibition or even emotional dysfunction, which are often 
observed in FTD patients (Przybyla et al., 2016). These findings illustrate the importance of 
objective evaluations of emotional behavior in mice along with a comprehensive analysis 
(including considering test confounders and false positive results), rather than a blunt 
matching to human symptoms to suggest translation. 
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Other clinically relevant behavioral changes in FTD may have correlates in FTD mouse 
models. Repetitive behavior is a clinical feature in FTD patients (Rascovsky et al., 2011), and 
may be represented in mice by abnormal repetitive grooming. For example, repetitive 
grooming has been reported in aged mutant tau-transgenic mice where it increases with age, 
and is hypothesized to reflect ventral striatum dysfunction (Warmus et al., 2014). 
Interestingly, this dysfunction correlates with the severity of repetitive behaviors in FTD 
patients (Josephs et al., 2008). Treatment of tau transgenic mice with the NMDA receptor co-
agonist cycloserine to increase NMDA receptor functioning significantly decreased 
grooming, as well as improved nest building and elevated plus maze performance in these 
mice, and was thought to mediate its effects through improving synaptic deficits in the 
striatum (Warmus et al., 2014). Over-grooming has also been observed in transgenic mice 
with forebrain-specific expression of FTD mutant CHMP2B.(Gascon et al., 2014) 
 
Socioemotional changes in FTD 
Socioemotional changes in humans 
Social dysfunction represents one of the hallmark features of FTD, with caregivers reporting 
prominent changes in social comportment, appropriateness, as well as reduced social interest 
leading to social withdrawal (Piguet et al., 2011). Altered emotion processing is widely 
documented in FTD patients, with recognition of negative emotions such as anger, fear, and 
disgust, predominantly affected (Kumfor et al., 2013; Werner et al., 2007). These difficulties 
extend beyond the recognition of facial emotional expressions and lead to a marked inability 
to empathize or to share the emotional experience of others (Dermody et al., 2016; Rankin et 
al., 2005). Recently clinical research in FTD has focused on the link between emotion 
processing and physiological changes in terms of autonomic function in FTD (Fletcher et al., 
2015; Guo et al., 2016). In addition, FTD patients have difficulty inferring the thoughts and 
beliefs of others (i.e., theory of mind) (Adenzato et al., 2010), resulting in an apparent lack of 
regard for the thoughts and feelings of others (Hsieh et al., 2013; Lough et al., 2006). 
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Mounting evidence suggests that these deficits map to medial prefrontal and right anterior 
temporal lobe pathology (Irish et al., 2014a; Rankin et al., 2006). 
 
Socioemotional changes in mouse models 
Reduced social engagement and aggression has been demonstrated in a number of GRN 
knockout mice (Filiano et al., 2013; Ghoshal et al., 2012; Petkau et al., 2012; Yin et al., 
2010), which may align with the social dysfunction observed in FTD. Interestingly, social and 
emotional dysfunction were attributed to impaired neuronal activation in the amygdala 
(Filiano et al., 2013). Mutant tau expressing mice have been reported to display impairments 
in the Crawley‟s social interaction test (a test examining sociability and social novelty 
(Crawley, 2004)) , suggestive of reduced sociability and/or impaired recognition memory 
(Takeuchi et al., 2011). Furthermore, mice expressing non-functional TDP-43 (lacking the 
nuclear localization sequence) in forebrain neurons displayed reduced sniffing behavior in the 
social interaction test (Alfieri et al., 2014). Reduced performance in the social interaction test 
has also been reported for mice expressing 66 G4C2 repeats to mimic C9ORF72 repeat 
expansion (Chew et al., 2015). Mice with forebrain-specific expression of mutant CHMP2B 
displayed reduced sociability as measured by the Crawley‟s social interaction test (Gascon et 
al., 2014). Together, these studies suggest that social dysfunction is a common phenotype 
across various FTD mouse models, unifying the different types of pathogenic transgenes 
expressed. Future research in this area could examine the applicability of physiological 
measures e.g., heart rate, skin conductance, pupillary response and autonomic function 
previously used in humans to examine social and emotional dysfunction, to mouse models. 
 
Memory dysfunction in FTD 
Memory dysfunction in humans 
Perhaps the most commonly studied cognitive function in dementia is episodic memory, 
which refers to the ability to consciously encode, store, and retrieve information regarding 
previously experienced events. Episodic memory dysfunction represents the hallmark feature 
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of Alzheimer‟s disease (AD), with marked deficits evident on standard neuropsychological 
tests of visual and verbal recall (de Toledo-Morrell et al., 2000; Irish et al., 2016) and the 
recall of personally relevant autobiographical memories (Irish et al., 2011b).  
 
Not surprisingly, mouse models of AD rely heavily on behavioral paradigms of hippocampal-
dependent learning and memory, with typical tasks such as the Morris water maze, radial arm 
maze, and novel object recognition tests (Gotz and Ittner, 2008). While crucial to functionally 
validate disease mechanisms, these behavioral paradigms have not been widely applied to 
FTD mouse models. This lack of research reflects a long-held, but erroneous, assumption that 
hippocampal functioning, and therefore episodic memory, is relatively spared in humans with 
FTD as reflected in the current diagnostic criteria for bvFTD (Rascovsky et al., 2011). 
Mounting evidence from neuroimaging and neuropsychological studies in humans, however, 
converge to reveal clear-cut episodic memory deficits in FTD (Hornberger and Piguet, 2012). 
Patients display memory impairment equivalent to that of matched AD cases across 
standardized tests of verbal and visual, immediate and delayed, recall (Hornberger et al., 
2010; Irish et al., 2014c; Pennington et al., 2011), and retrieval of autobiographical events 
from the past (Irish et al., 2011a; Irish et al., 2014b). These deficits extend to the domain of 
source memory, with bvFTD patients being unable to correctly retrieve the spatial or temporal 
context of previously presented items (Irish et al., 2012a; Söderlund et al., 2008). Recently it 
has been suggested that verbal impairments in FTD may confound memory function (Baldock 
et al., 2016), however verbal deficits tend to occur late in the bvFTD disease course. Further, 
while initially it was assumed that episodic memory impairments in bvFTD stemmed from 
the degeneration of prefrontal cortical regions (Pennington et al., 2011; Simons et al., 2002), 
it is becoming increasingly clear that the hippocampus and anterior and medial temporal 
regions are also involved (Frisch et al., 2013; Irish et al., 2014c). As such, we propose that the 
long-standing view that behavioral paradigms of hippocampal-dependent learning in FTD 
mouse models are not relevant to clinical FTD warrants revision 
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Memory dysfunction in mouse models 
Classic episodic memory based tests such as the Morris water maze have, in fact, 
demonstrated memory impairments in several FTD mouse models, such as for mutant tau 
(Santacruz et al., 2005; Tatebayashi et al., 2002), TDP-43 (Swarup et al., 2011) and VCP 
transgenic (Custer et al., 2010; Rodriguez-Ortiz et al., 2013), and GRN knockout mice 
(Ghoshal et al., 2012; Wils et al., 2012; Yin et al., 2010). A new and increasingly popular 
method of assessing cognitive function in mice is through the use of automated touchscreen 
operant chambers, which involve training animals to use touchscreen platforms to respond to 
various stimuli presented on a screen to receive a food reward (Horner et al., 2013; Mar et al., 
2013; Oomen et al., 2013). In many cases, these tasks are similar to those used in human 
cognitive testing (e.g., Cambridge neuropsychological test automated battery) and can be used 
to assess a range of neuropsychological functions, such as learning, memory, attention and 
cognitive flexibility. A further benefit of this technique is the low stress levels involved, due 
to appetitive (positive) rather than aversive reinforcement. Although the technique may have 
high translational potential (Horner et al., 2013; Mar et al., 2013; Oomen et al., 2013), it is 
labor- and cost-intensive, and trials often take many weeks of continual testing. Therefore, 
other paradigms, such as the radial arm maze, T-maze and Barne‟s maze that cause 
significantly less stress than, for example, the Morris water maze, remain valid alternatives. 
Nevertheless, automated and standardized memory testing may overcome the limited 
comparability of other non-standardized tests, allowing cross-comparison between the various 
tasks and FTD mouse models. To date, automated touchscreen operant chambers have not 
been used in FTD mouse models. Testing well-defined human FTD cohorts and 
corresponding transgenic mouse models of FTD in parallel using similar touchscreen test 
protocols may therefore serve to increase our understanding of the cognitive deficits in 
humans with FTD and the underlying molecular mechanisms in mice. 
 
Language impairment in FTD 
Language impairment in humans 
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Language impairment in FTD is complex with 2 distinct clinical presentations: svPPA 
associated with progressive breakdown of the semantic memory (the memory system that 
stores knowledge about objects and words) and PNFA by a progressive breakdown in speech 
output with effortful, non-fluent speech, characterized by agrammatism, and/or problems with 
motor-based speech planning, termed apraxia of speech, characterized by groping, 
segmentation and loss of prosody (Ash et al., 2009; Josephs et al., 2006a). Mutations in 
FOXP2 have been associated with severe language deficits (Lai et al., 2003). Interestingly, 
FOXP2 polymorphisms, although not constituting a genetic risk for FTD, when present, 
reduce language performance and impact on perfusion of language-associated brain areas in 
overt FTD (Padovani et al., 2010; Premi et al., 2012). Both FOXP2 protein and mRNA were 
found to be reduced in the frontal cortex in a small cohort of FTD with tau pathology and 
language impairment (Lopez-Gonzalez et al., 2016). 
 
Language impairment in mouse models 
Examining language in mouse models is complex. An interesting example of a clinical 
symptom-driven approach was provided by Menuet et al, who examined whether language 
anomalies in FTD patients have a correlate in tau transgenic mouse models (Menuet et al., 
2011). The study found impaired ultrasonic vocalizations in aged mutant tau mice, which 
correlated with tau pathology in midbrain and brainstem nuclei controlling vocalization and 
respiration (Menuet et al., 2011). This may partially resemble the language disorders 
observed in FTD patients, and awaits confirmation in other lines. It would also be interesting 
to determine how altered vocalization in tau transgenic mice is affected by tau-targeted 
therapeutic intervention. The degree to which muscle anomalies of the larynx contribute to 
impaired vocalization remains unclear, especially as wasting of large muscles has been 
reported in several tau transgenic lines (Ittner et al., 2008; Lewis et al., 2000; Probst et al., 
2000). Showing parallels to FTD in humans, both FOXP2 protein and mRNA levels were 
reduced in mutant tau transgenic mice (Lopez-Gonzalez et al., 2016). Furthermore, 
heterozygous depletion of FOXP2 or mutant FOXP2 knockin in mice resulted in altered 
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ultrasonic vocalization, while learning and memory appeared normal (Fujita et al., 2008; Shu 
et al., 2005). These findings suggest that ultrasonic vocalization in mice, although not 
resembling the complexity of human language, may be an according readout in mice to study 
molecular mechanisms underlying language changes in FTD, for example by crossing mutant 
FOXP2 mice with FTD models. Yet, the ability to examine semantic deficits in mouse models 
remains limited, and other approaches examining behavioral responses to vocalisations and 
learned “rules” and “syntax” may prove fruitful. Recent models have attempted to examine 
semantic knowledge using food preference studies (Koss et al., 2016), however this approach 
is problematic given the changes in food preference that are seen in both bvFTD and svPPA. 
The origins of such changes are inherently complex, attributable to neural atrophy in 
orbitofrontal cortex, hypothalamus reward structures, and regions supporting semantic 
knowledge (Ahmed et al., 2016b). Taken together, mouse models may contribute to the 
understanding of underlying mechanisms in semantic deficits in FTD by using ultrasonic 
vocalization as a surrogate readout for changes in „language‟ formation, but it is unlikely that 
using a single one species will ever capture the complexity of human language. As such, the 
study of species with more complex vocalization patterns (e.g. song birds) may prove helpful 
to elucidate language features of FTD.  
 
Eating behavior and metabolism in FTD 
Eating behavior and metabolism in humans 
Alterations in eating behavior (hyperphagia or preference for sweet foods) are one of the 
diagnostic criteria for bvFTD (Ahmed et al., 2014a; Ahmed et al., 2016b; Ahmed et al., 
2016c; Ikeda et al., 2002; Rascovsky et al., 2011). It is increasingly recognized that such 
changes are also present in sv-PPA (Ahmed et al., 2014a; Ikeda et al., 2002). Eating changes 
affect metabolism and possibly disease progression and prognosis (Ahmed et al., 2014b). 
Patients with FTD and in particular bvFTD have been shown to have an increased body mass 
(BMI) index, which has been suggested anecdotally to be less than expected for their caloric 
intake. Changes in HDL cholesterol and triglyceride levels, with increased fasting serum 
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insulin, further suggest a state of insulin resistance (Ahmed et al., 2014b). In ALS a 
contrasting metabolic pattern has been observed including a state of hypermetabolism 
(Desport et al., 2005), with low BMI (Dupuis et al., 2011; Jawaid et al., 2010a), but similarly 
to FTD, hyperlipidemia including increased triglyceride levels (Dupuis et al., 2008) and 
peripheral insulin resistance (Jawaid et al., 2010b). These variables have been found to affect 
disease progression in ALS with an increased triglyceride level (Dorst et al., 2011), increased 
low density lipoprotein (LDL) to high density lipoprotein (HDL) ratio (Dupuis et al., 2008) 
and the presence of diabetes mellitus thought to be protective against disease progression 
(Dupuis et al., 2008; Jawaid et al., 2010b). In ALS, low BMI has been associated with worse 
prognosis; however, it has also been shown that as ALS patients develop cognitive 
impairment, their BMI increases, suggesting that BMI patterns in ALS in addition to being 
influenced by peripheral factors, such as muscle wasting, may be centrally mediated (Ahmed 
et al., 2014c). 
 
Eating behavior and metabolism in mouse models 
A detailed understanding of eating behavior and metabolic changes in current FTD mouse 
models is lacking. There is the suggestion that metabolic changes may be associated with the 
process of neurodegeneration with several mouse models including TDP-43 and C9ORF72 
associated with weight loss (Chew et al., 2015; Chiang et al., 2010; Dupuis et al., 2004; Shan 
et al., 2010; Xu et al., 2010). Recent studies have also shown that high fat diet-induced 
obesity exacerbates tau pathology in mutant tau transgenic mice (Koga et al., 2014; 
Leboucher et al., 2013). Similarly, it has being shown that diabetes exacerbates tau deposition 
(Ke et al., 2009), suggesting cross-talk between metabolism and brain pathology in FTD. 
Furthermore, recent studies in normal mice have suggested that both excitatory and inhibitory 
input to similar neural correlates to those suggested to be involved in humans with FTD 
(Ahmed et al., 2015; Perry et al., 2014) results in hyperphagic behavior and sucrose 
preference, showing that the lateral hypothalamus connects to the reward centers in the 
ventral tegmental area, that may mediate sucrose preference (Nieh et al., 2015). Future studies 
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need to determine the effects of neuronal expression of FTD mutant proteins on metabolic 
parameters and regulation of weight in mice, potentially providing important insights as to 
what controls eating and metabolism in FTD.  
 
Several ALS mouse models also present with alterations in energy metabolism. For example, 
mutant SOD1 mouse models demonstrate hypermetabolism (Dupuis et al., 2004), with a 
delayed disease onset and increased survival mediated by a high fat diet, while caloric 
restriction shortens the lifespan and induces lipid peroxidation, inflammation and apoptosis 
(Dupuis et al., 2004; Patel et al., 2010). A recent study in ALS (Vercruysse et al., 2016) 
revealed that hypothalamic neurons producing proopiomelanocortin (POMC) were decreased 
and the endogenous melanocortin inhibitor agouti-related peptide (AGRP) (a known appetite 
stimulator), increased in mice expressing amyotrophic lateral sclerosis-linked mutant 
SOD1(G86R). Consistent with a defect in the hypothalamic melanocortin system, food intake 
after short-term fasting was increased in SOD1(G86R) mice. These findings were replicated 
in two other amyotrophic lateral sclerosis mouse models based on TDP-43 (Tardbp) and FUS 
mutations. These findings show a potential correlation with human studies with AGRP found 
to be elevated in FTD patients and associated with abnormal eating behavior and changes in 
BMI (Ahmed et al., 2015). 
 
Motor Symptoms and FTD 
Motor symptoms in humans 
Motor symptoms are a common feature of FTD; a significant proportion of patients develop 
symptoms reminiscent of Parkinson‟s disease (i.e., parkinsonism) (Siuda et al., 2014), and 
FTD and ALS are part of a disease continuum with overlapping clinical presentations (Burrell 
et al., 2016). Accordingly, 10-15% of FTD patients have concomitant ALS, while 25-60% 
show evidence of motor neuron dysfunction insufficient to reach criteria for ALS (Burrell et 
al., 2011; Josephs et al., 2006b; Lomen-Hoerth et al., 2002). Conversely, cognitive testing of 
ALS patients revealed frequent frontal executive (Ringholz et al., 2005) and language deficits 
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(Caselli et al., 1993) (Duffy et al., 2007), and behavioral features including apathy, loss of 
empathy, emotional lability and, less commonly, gluttony, behavioral stereotypes and 
compulsions (Gibbons ZC, 2008), typical of FTD. Therefore, it has been suggested that FTD 
and ALS represent extremes of a disease spectrum (Clark and Forman, 2006). Between 10-
50% of FTD patients develop features of parkinsonism (Siuda et al., 2014), most frequently 
observed in „FTD with Parkinsonism linked to chromosome 17q‟ (FTDP-17) (Wszolek et al., 
2006), with mutations also identified in MAPT and GRN (Siuda et al., 2014). Furthermore, 
poly-GC-repeat expansions in C9ORF72 have been associated with parkinsonism (Park and 
Chung, 2013). At autopsy, ALS-like motor symptoms are typically associated with TDP-43 
pathology, while parkinsonism tends to be associated with tau pathology (Siuda et al., 2014).  
 
Motor symptoms in mouse models 
Interestingly, motor deficits were the first prominent motor phenotype described in non-
mutant and mutant tau transgenic mouse models of FTD [ALZ17, JNPL3] (Lewis et al., 2000; 
Probst et al., 2000). In several of the tau models, motor deficits have been described in 
association with muscle weakness and postural changes [JNPL3(P301L)] (Lewis et al., 2000), 
paraparesis [Tau P301S (Line PS19)] (Yoshiyama et al., 2007) and dystonic features [Tau 
R406W] (Tatebayashi et al., 2002). Furthermore, we have described an FTD mutant line, K3, 
which developed all aspects of FTD-associated parkinsonism including early resistance to L-
dopa treatment (Ittner et al., 2008). These mouse models have been instrumental in 
developing tau-targeted treatments, in particular due to the early-onset progressive motor 
phenotype (Ittner et al., 2015; van Eersel et al., 2010). Other FTD mouse models have 
presented with motor deficits. For example, TDP-43 transgenic mouse models are reported to 
show a wide range of changes from limited motor impairments (Wegorzewska et al., 2009), 
decreased grip strength and gait abnormalities, to profound muscle weakness (Tsao et al., 
2012; Wegorzewska et al., 2009; Wils et al., 2010; Xu et al., 2010). This includes more recent 
mutant TDP-43 mouse models with controllable transgene expression and rapid development 
of motor and behavioral deficits, together with FTD-like biochemical and histopathological 
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changes (Ke et al., 2015; Walker et al., 2015). It would be of interest to differentiate between 
motor phenotypes due to muscle wasting, and those resulting from neuronal dysfunction. 
Here, the association of motor deficits and atrophy/pathology of specific brain regions in 
human FTD may assist in analyzing specific brain area and structures in FTD mouse models, 
to elucidate underlying molecular pathomechanisms. Furthermore, motor phenotypes in FTD 
mouse models, even if not resembling a dominant clinical feature of the human disease, 
should be used as simple functional surrogate readouts for molecular studies and drug 
development (van Eersel et al., 2010).  
 
 
Future directions 
While commonly used constitutively expressing FTD mouse models have been instrumental 
in studying biochemical and histological aspects of FTD and to test therapeutic interventions, 
they have certain limitations. For example, spread of neuropathological changes which has 
been documented in humans is difficult to replicate in mouse models with the „all or none‟ 
pattern of constitutive transgene expression. This is of particular relevance given the 
increasing interest in pathological spread in a prion-like manner and network involvement in 
FTD and ALS. (Braak et al., 2013; Ludolph and Brettschneider, 2015; Tan et al., 2015). It is 
increasingly recognized that FTD, rather than reflecting a single protein or neuronal area, 
represents systems or network degeneration (Ahmed et al., 2016a; Eisen and Turner, 2013; 
Irish et al., 2012b; Warren et al., 2013). Models proposed include “molecular nexopathies” 
which suggests that proposed deposition and propagation of proteins along particular 
networks potentially in a prion-like manner is responsible for phenotypic FTD presentations 
(Warren et al., 2013). The extension of proposals such as this into animal models offers the 
potential to not only understand different phenotypic presentations in FTD, but also to trial 
treatments targeted at particular networks and examine the effects of developmental, 
environmental and social modifications on the expression of disease phenotypes.  
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Neuronal network aberrations have been described for transgenic mouse models using 
electroencephalography (Hall et al., 2015), imaging (Busche et al., 2008), and computational 
methods to mine EEG data for network performance. Several recording types appear 
particularly relevant as their network features and can be related to cognitive performance by 
computational means; hippocampal recordings from the cornu ammonis (CA) region for 
example provide insight on performance and topology of pyramidal/interneuronal 
connections that are reflected in EEG gamma and theta oscillations and their phase-coupling 
(Buzsaki and Moser, 2013). Spontaneous and induced hyperexcitability have also been 
observed in tau transgenic mouse models (Garcia-Cabrero et al., 2013). However, detailed 
analysis of network topology by EEG or electrophysiology of single cells in situ in tau 
transgenic mice has not been performed. Network alterations in FTD mouse models using, 
TDP-43 overexpression or C9ORF72 repeat expansion have also not been addressed. 
Recently optogenetics have made manipulation of neuronal systems in vivo feasible (Marton 
and Sohal, 2015). Combining functional network analysis by EEG, electrophysiology or 
imaging with induced changes in activity of specific neuronal ensembles by optogenetics is 
likely to prove a valuable tool to address whether network aberrations can be manipulated or 
even reversed by specifically targeting subsets of neurons (e.g. interneurons). Insights from 
these induced network outputs can then be correlated with cognitive performance.  
 
The use of transgenic promoters with high expression levels, which may be needed to achieve 
pathology within the life-time of a mouse, limits the ability of cells to regulate protein levels, 
including during brain development. Although, mutant proteins may be similarly present 
during development in human mutation carriers, unphysiological levels at embryonic and/or 
early post-natal stages may have developmental effects that contribute to later phenotypes 
(Cannon et al., 2012). Using inducible promoters and expression in mature brains is an 
elegant way to circumvent this problem, and has been used in a number of more recent tau 
and TDP-43 transgenic mouse models (Santacruz et al., 2005; Xu et al., 2010). Notably, we 
have recently used inducible human mutant TDP-43 mice to show that short term suppression 
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of pathological TDP-43 results in significant improvements of functional deficits, supporting 
the development of future compounds that target TDP-43 directly to treat FTD (Ke et al., 
2015). Furthermore, the availability of advanced genome-editing technologies, such as 
CRISPR (LaFountaine et al., 2015), allows simple introduction of pathogenic mutations into 
endogenous mouse genes, or exchange parts or whole loci to humanize the murine gene 
product, while still using endogenous promoters, as recently reported for the amyloid-β 
precursor protein (APP) locus (Saito et al., 2014). Similar humanized FTD models may 
advance our current understanding of the disease and overcome limitations of current 
transgenic lines.  
 
While some human FTD cases present with a single type of pathology at autopsy, the 
heterogeneity of the disease, both pathologically and clinically, is remarkable (Rohrer et al., 
2011). Typically, transgenic mouse models express one pathogenic factor, such as mutant tau 
or TDP-43, which assist in understating specific disease mechanism, but limits translation to 
the heterogeneous pathology seen in humans. Combinatorial approaches, by intercrossing 
different transgenic lines, have had a significant impact on understanding disease mechanisms 
in AD (Ittner et al., 2010; Kulic et al., 2011; Lewis et al., 2001; Oddo et al., 2003). Similar 
combinatorial approaches utilizing existing FTD models with different transgenes, or in the 
future by introducing multiple humanized FTD genes, may provide a similar advance in 
understanding the pathogenesis of FTD.  
 
As outlined above, the clinical presentation of FTD includes a wide range of functional 
changes, with behavioral, memory, language, eating/metabolic, and motor deficits, in addition 
to variable neuropathology. Here, FTD mouse models may only recapitulate single or a small 
number of the clinical features. Accordingly, few FTD mouse model studies have attempted 
to address multiple aspects of the clinical symptoms, focusing instead on specific phenotypes. 
While this appears to be a disadvantage at first sight, it offers the opportunity to reduce the 
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complexity of the human disease to tractable „building blocks‟ and allows studying 
underlying mechanisms of distinct aspects of disease. Combinations of models may then be 
used to „rebuild‟ the complexity of the human disease and inform the cross-impact of 
individual aspects on each other, to eventually elucidate FTD in its entirety. Future studies of 
FTD mouse models should consider overlapping, including comprehensive functional testing 
with complementary paradigms. Furthermore, using established associations between 
functional deficits and localization of pathology in human FTD should guide the functional 
analysis of mouse models, rather than retrospective matching of phenotypes to clinical 
symptoms and pathology. The development of new techniques to examine differing 
functional deficits across multiple domains (Table 2) may improve hypothesis testing and 
translation, and thus advance our understanding of human pathophysiology. 
 
Inter-individual genetic and environmental variability in humans contributes to significant 
differences in disease presentation across patients, including for example incomplete 
penetrance in C9ORF72 mutation carriers or varying age of onset (Hodges, 2012).Typically, 
when generating transgenic mouse models of FTD and other diseases, researchers go to great 
lengths to achieve identical genetic backgrounds, that is by backcrossing on defined inbred 
strains (such as C57BL/6J) over more than 10 generations, in order to control for variability 
and reduce the sample sizes needed to carry out an experiment. This is particularly important 
for behavioral testing, where variability in genetic backgrounds could result in inconsistent 
results and the need for very large group sizes. While advocating for clean genetic 
backgrounds when establishing new transgenic mouse lines, inbred lines likely fail to capture 
varying phenotypes due to the impact of environmental factors on genetic variability. 
Utilizing new platform resources with defined variability of genetic backgrounds in mice, 
such as the Collaborative Cross may in the future allow genetic modifiers in FTD mouse 
models to be addressed (Bogue et al., 2015) to provide new insight into the pathological and 
clinical variability of FTD in humans. Such approaches, however, are labor-, resource- and 
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cost-intensive and will depend on well-defined models of FTD with highly penetrant 
phenotypes, and are therefore only likely to succeed within large research collaborations. 
Another approach may be to use the concept of endophenotypes which are heritable traits that 
are considered to be more highly associated with a gene based neurological deficit than a 
disease phenotype itself. These endophenotypes can be present in the non- affected relatives 
of patients affected with disease and suggestions have been made to utilize this approach in 
diseases such as schizophrenia (Amann et al., 2010; Desbonnet et al., 2009). This approach 
may aid in understanding underlying disease pathomechanisms and trialing treatments. 
Taken together, we propose that an approach of (re-)examining FTD mouse models based on 
functional impairment in human patients will help to elucidate the underlying process of 
neurodegeneration in FTD (Figure 1). Examining FTD mouse models driven by functional 
impairment from humans across multiple pathologies and genetic changes will elucidate the 
specific networks involved and therefore may have greater clinical applicability. Defining 
FTD mouse models, in isolation or in combination, based on functional deficits driven by 
clinical observations may also improve drug development and testing. Therefore, 
complementing the current neuropathology-driven approach of matching pathology to single 
symptoms with a more functional approach offers unique potential to improve translation of 
animal models to humans. We suggest that this approach will aid the development of new 
therapeutic strategies in the hope of modifying disease prognosis and progression. 
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Table 1: Clinical and imaging features of FTD 
 
 bvFTD sv-PPA PNFA AD for 
comparison 
 Cognitive Domains 
Episodic 
memory 
++ intact intact +++ 
Executive 
function 
+++ intact intact ++ 
Orientation intact intact intact +++ 
Spatial memory intact intact intact +++ 
Eating 
behavior 
+++ ++ + intact 
Emotion 
processing 
+++ +++ + + 
Theory of mind +++ ++ intact intact 
Empathy +++ ++  intact 
Language  Can develop 
semantic 
deficits 
Prominent 
semantic deficits 
Non-fluent 
spontaneous 
speech, 
agrammatism, 
apraxia of 
speech, 
anomia. 
 
Can present with 
language 
impairment 
Predominant 
areas of 
atrophy 
Frontoinsular 
cortices, medial 
prefrontal 
cortex, 
spreading to 
include lateral 
and medial 
temporal 
regions 
including 
hippocampus 
Anterior 
temporal 
cortices 
(asymmetric). 
Including 
hippocampus, 
spreads to 
contralateral 
hemisphere and 
ventromedial 
prefrontal 
cortex. 
Asymmetric 
changes 
affecting the 
dominant 
hemisphere, 
usually left 
sided 
Medial temporal 
lobes (entorhinal, 
parahippocampal, 
hippocampus), 
posterior parietal 
cortices, spreads to 
frontal and lateral 
temporal lobes. 
Predominant 
pathological 
protein 
deposition 
TDP-43, Tau, 
FUS 
TDP-43 type C Tau or TDP-
43 type A 
Tau and amyloid 
 
bvFTD= behavioural variant frontotemporal dementia; sv-PPA= semantic variant 
primary progressive aphasia; PNFA= progressive non-fluent aphasia; AD= Alzheimer’s 
disease. Number of + reflects degree of deficit reported in the literature, increasing 
number of + reflects increasing deficits. 
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Table 2: Potential approaches to examine functional deficits between humans and mouse models 
 
 
Functional domains  Deficits in humans with FTD Deficits shown in mouse models Extended approaches to examine 
these domains in mouse models  
Behaviour Pervasive behavioral changes, 
apathy, disinhibition, impulsivity, 
executive dysfunction 
Hyperactivity, apathy, anxiety, 
repetitive behaviors (Cook et al., 
2014; Pennanen et al., 2006; 
Przybyla et al., 2016; Van der 
Jeugd et al., 2016).  
Complex test batteries to exclude 
confounding memory/motivation 
deficits; automated touchscreen 
operant chambers. 
Socioemotional cognition Deficits in emotion processing, 
lack of empathy 
Reduced sociability(Alfieri et al., 
2014; Chew et al., 2015; Filiano et 
al., 2013; Gascon et al., 2014; 
Takeuchi et al., 2011) 
Skin conductance, pupillary response, 
autonomic function in relation to 
emotional stimuli 
Memory Episodic memory deficits 
increasingly recognised 
Episodic memory deficits shown 
on water maze test (Custer et al., 
2010; Ghoshal et al., 2012; 
Santacruz et al., 2005; Swarup et 
al., 2011). 
automated touchscreen operant 
chambers 
Language Deficits in semantic knowledge 
and speech output depending on 
variant. 
Reduced vocalisations(Menuet et 
al., 2011) 
Explore mouse vocalisations in 
different test paradigms 
Eating and metabolism Hyperphagia, rigidity, sucrose 
preference. Suggestion less weight 
gain than expected for intake 
Eating behaviour not examined. 
Several models show weight 
loss(Chew et al., 2015; Chiang et 
al., 2010). Diet may alter tau 
deposition (Koga et al., 2014; 
Leboucher et al., 2013). Several 
ALS models show 
hypermetabolism(Dupuis et al., 
2004; Patel et al., 2010) 
Analyses of weight, fat composition, 
dietary intake and nutrient preference; 
metabolic cages 
Motor Parkinsonism, muscle weakness Weakness, dystonia, Parkinsonism Examine for relationship between 
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and ALS. (Ittner et al., 2015; Ittner et al., 
2008; Lewis et al., 2000; 
Tatebayashi et al., 2002; Tsao et 
al., 2012) 
muscle wasting weakness and 
parkinsonian features 
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Figure 1: Mouse models and reported functional deficits 
 
Figure showing the functional impairments reported in available mouse models and future directions for research to improve clinical and pathological utility 
of mouse models. 
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